project success rate
sequencing success rate
scale production
expression yield improvement
From AI-powered antibody design to GMP-ready manufacturing and bioactivity validation — every step under one roof.
De novo antibody generation, affinity maturation, and humanization powered by our proprietary antibody LLM. In silico design closes the loop with wet-lab expression and functional validation.
Explore AI antibody design service →Full antibody discovery from antigen to hit, plus sequence recovery from hybridoma or recombinant sources via NGS, LC-MS/MS, and Sanger. Industry-leading 99% antibody sequencing success rate.
Explore antibody discovery & sequencing →Proprietary CHO cell line with CRISPR site-specific integration and UCOE technology. Deterministic, high-yield stable expression — no random integration variability, no gene silencing.
Explore stable cell line development →Transient and stable recombinant protein expression using optimized CHO cell systems. From mg-scale feasibility to gram-scale antibody expression, with >95% purity guaranteed.
Explore recombinant protein expression →Scalable recombinant monoclonal antibody production from mg to kg scale. Consistent batch quality with full analytical characterization, release testing, and bioactivity confirmation.
Explore monoclonal antibody production →White-label contract antibody manufacturing for IVD companies and biotech. Flexible OEM antibody manufacturing with NDA protection, full quality documentation, and regulatory support.
Explore OEM antibody manufacturing →AntibodyLLM's antibody sequencing service recovers your antibody variable region sequences (VH/VL) with an industry-leading 99% success rate. We do not deliver unverified sequences — every result passes our internal functional verification pipeline. Sequence confirmed, activity validated, then delivered.
Hybridoma cells, purified antibody, or serum
NGS / LC-MS/MS / Sanger — VH & VL recovery
Recombinant expression to confirm sequence identity
ELISA, SPR, or cell-based assay — in-house
Sequence report + activity data — no third parties
Not random integration. Not unstable expression. Engineered. Controlled. Scalable.
Our in-house CHO cell line is engineered for high-yield antibody expression and industrial scalability. Purpose-built for recombinant antibody and protein production, it delivers consistent output from mg to kg scale with >95% purity.
CRISPR-guided insertion targets a defined, transcriptionally active genomic locus — eliminating the clonal variability caused by random integration. Every stable cell line is built from the same engineered foundation, reducing screening time by up to 50%.
Ubiquitous Chromatin Opening Elements (UCOE) maintain an open chromatin state at the integration site, preventing gene silencing during long-term culture. The result is stable, long-term expression without the drift that plagues conventional stable cell lines.
Deterministic expression, not random screening
Learn more on our technology platform page
A closed-loop system integrating AI design with wet-lab reality:
From in silico to in vitro — seamlessly.
Antibody bioactivity validation is the functional confirmation that your antibody binds its target with specificity and triggers the intended biological response. AntibodyLLM's weblab runs all validation in-house — no outsourcing, no delays, full traceability.
Quantitative antigen-binding confirmation. Direct, indirect, sandwich, and competition ELISA formats for specificity and titer determination. First-line screen for all antibody sequencing and production projects.
Surface plasmon resonance (SPR) for real-time, label-free measurement of association rate (ka), dissociation rate (kd), and equilibrium dissociation constant (KD). Critical for affinity ranking and lead selection.
Receptor blocking, ADCC/CDC, cell viability, and proliferation assays to confirm biological activity in relevant cellular models. Essential for therapeutic antibody development and IVD antibody qualification.
Every antibody we deliver comes with bioactivity data.
No third-party labs. No black boxes. Full traceability from sequence to functional proof — all under one roof.
Learn about our AI antibody design service →For a leading biotech client's stable cell line project using our CRISPR site-specific integration platform.
View case study →Rescued multiple hybridoma sequencing projects that competitors deemed impossible. Sequence-verified and activity-confirmed before delivery.
Learn about sequencing →Cut typical R&D timelines by half for IVD clients through our one-stop sequencing-to-validation pipeline.
View case study →Everything you need to know about AntibodyLLM's platform and services.
AI antibody design uses large language models (LLMs) trained on protein sequence and structure data to generate, predict, and optimize antibody sequences in silico. AntibodyLLM's platform combines AI-generated candidates with wet-lab expression and bioactivity validation in a closed-loop workflow — dramatically reducing design cycles compared to traditional hybridoma or phage display methods. The result: faster lead generation, lower cost, and higher hit rates.
Antibody sequencing recovers the precise variable region sequences (VH and VL) of an antibody from hybridoma cells or purified protein. AntibodyLLM achieves a 99% antibody sequencing success rate using NGS deep sequencing, LC-MS/MS, and Sanger methods matched to your sample type. We only deliver sequences that have passed our internal verification — expression-confirmed and bioactivity-validated in our weblab before the final report is handed over. No unverified sequences, ever.
Recombinant protein expression is the production of a target protein by introducing its gene into a host cell system — typically CHO, HEK293, or E. coli — and inducing protein production at scale. AntibodyLLM uses optimized CHO cell systems for both transient and stable antibody expression, delivering >95% purity from mg-scale feasibility studies to gram-scale manufacturing. Our proprietary CRISPR-integrated CHO cell lines ensure consistent, high-yield output batch to batch.
AntibodyLLM's in-house weblab performs full bioreactivity validation including ELISA for binding specificity and titer, SPR (surface plasmon resonance) for real-time kinetics (ka, kd, KD), and cell-based functional assays for receptor blocking, ADCC, and biological activity. All validation is conducted in-house — no third-party outsourcing — ensuring faster turnaround, complete data traceability, and a single point of accountability from sample to result.
Stable cell line development creates a host cell (typically CHO) that permanently expresses your antibody or protein of interest — essential for consistent, scalable biopharmaceutical manufacturing. AntibodyLLM uses CRISPR site-specific integration and UCOE (Ubiquitous Chromatin Opening Element) technology to eliminate random integration and gene silencing. The result is a deterministic, high-yield CHO cell line with 95%+ project success rate and up to 3× improvement in expression yield versus conventional stable cell line methods.
Yes. AntibodyLLM offers white-label OEM antibody manufacturing for IVD companies, diagnostics developers, and biotech firms. Our OEM/ODM service covers cell line development, scale-up production, analytical characterization, bioactivity validation, and packaging under NDA. We support mg to kg quantities with full quality documentation and regulatory support. Contact us to discuss your OEM antibody manufacturing requirements.
From AI antibody design to sequence-verified delivery and bioactivity validation — one team, one platform, zero outsourcing.